FDA Clarifies Endpoints in Non-Small Cell Lung Cancer Clinical Trials

Drug Industry Daily
A A
While overall survival remains the desired endpoint in treating non-small cell lung cancer, progression-free survival may suffice as the primary endpoint, the FDA says.

To View This Article:

Login

Subscribe To Drug Industry Daily